Pathogenic SCN2A variants cause early-stage dysfunction in patient-derived neurons.


Journal

Human molecular genetics
ISSN: 1460-2083
Titre abrégé: Hum Mol Genet
Pays: England
ID NLM: 9208958

Informations de publication

Date de publication:
19 06 2023
Historique:
received: 14 11 2022
revised: 23 02 2023
accepted: 19 03 2023
medline: 22 6 2023
pubmed: 4 4 2023
entrez: 3 4 2023
Statut: ppublish

Résumé

Pathogenic heterozygous variants in SCN2A, which encodes the neuronal sodium channel NaV1.2, cause different types of epilepsy or intellectual disability (ID)/autism without seizures. Previous studies using mouse models or heterologous systems suggest that NaV1.2 channel gain-of-function typically causes epilepsy, whereas loss-of-function leads to ID/autism. How altered channel biophysics translate into patient neurons remains unknown. Here, we investigated iPSC-derived early-stage cortical neurons from ID patients harboring diverse pathogenic SCN2A variants [p.(Leu611Valfs*35); p.(Arg937Cys); p.(Trp1716*)] and compared them with neurons from an epileptic encephalopathy (EE) patient [p.(Glu1803Gly)] and controls. ID neurons consistently expressed lower NaV1.2 protein levels. In neurons with the frameshift variant, NaV1.2 mRNA and protein levels were reduced by ~ 50%, suggesting nonsense-mediated decay and haploinsufficiency. In other ID neurons, only protein levels were reduced implying NaV1.2 instability. Electrophysiological analysis revealed decreased sodium current density and impaired action potential (AP) firing in ID neurons, consistent with reduced NaV1.2 levels. In contrast, epilepsy neurons displayed no change in NaV1.2 levels or sodium current density, but impaired sodium channel inactivation. Single-cell transcriptomics identified dysregulation of distinct molecular pathways including inhibition of oxidative phosphorylation in neurons with SCN2A haploinsufficiency and activation of calcium signaling and neurotransmission in epilepsy neurons. Together, our patient iPSC-derived neurons reveal characteristic sodium channel dysfunction consistent with biophysical changes previously observed in heterologous systems. Additionally, our model links the channel dysfunction in ID to reduced NaV1.2 levels and uncovers impaired AP firing in early-stage neurons. The altered molecular pathways may reflect a homeostatic response to NaV1.2 dysfunction and can guide further investigations.

Identifiants

pubmed: 37010102
pii: 7100037
doi: 10.1093/hmg/ddad048
pmc: PMC10281746
doi:

Substances chimiques

NAV1.2 Voltage-Gated Sodium Channel 0
Sodium 9NEZ333N27
Sodium Channels 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2192-2204

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Références

Nat Neurosci. 2009 Aug;12(8):996-1002
pubmed: 19633666
Brain. 2017 May 1;140(5):1316-1336
pubmed: 28379373
Neurology. 2010 Oct 19;75(16):1454-8
pubmed: 20956790
JCI Insight. 2021 Aug 9;6(15):
pubmed: 34156984
Front Mol Neurosci. 2019 Jun 04;12:145
pubmed: 31249508
Hum Mol Genet. 2014 May 15;23(10):2527-41
pubmed: 24381312
Hum Mol Genet. 2022 Aug 25;31(17):2964-2988
pubmed: 35417922
Epilepsia. 2008 Mar;49(3):488-99
pubmed: 18031550
Cerebellum. 2013 Feb;12(1):16-26
pubmed: 22528969
Cell. 2020 Feb 6;180(3):568-584.e23
pubmed: 31981491
J Clin Invest. 2021 Dec 1;131(23):
pubmed: 34850743
Neuroscience. 2001;102(2):307-17
pubmed: 11166117
Commun Biol. 2018;1:96
pubmed: 30175250
Nature. 2006 Dec 7;444(7120):707-12
pubmed: 17151658
Nat Rev Neurosci. 2010 Jan;11(1):18-29
pubmed: 19953103
Physiol Rev. 2008 Oct;88(4):1407-47
pubmed: 18923186
Elife. 2020 Jun 17;9:
pubmed: 32553116
J Physiol. 1992 May;450:643-72
pubmed: 1359126
Trends Neurosci. 2018 Jul;41(7):442-456
pubmed: 29691040
Sci Rep. 2019 Sep 9;9(1):12886
pubmed: 31501495
Mol Med. 2019 Feb 27;25(1):6
pubmed: 30813884
Genome Med. 2021 Aug 23;13(1):135
pubmed: 34425903
Bioinformatics. 2014 Feb 15;30(4):523-30
pubmed: 24336805
J Neurophysiol. 2022 May 1;127(5):1388-1397
pubmed: 35417276
J Neurosci. 2012 Jun 27;32(26):8940-51
pubmed: 22745494
J Neurosci. 2021 Dec 8;41(49):10194-10208
pubmed: 34716231
Nat Rev Neurosci. 2021 Mar;22(3):152-166
pubmed: 33531663
J Neurosci. 2010 Jul 28;30(30):10233-42
pubmed: 20668206
Biophys J. 2000 Jun;78(6):2878-91
pubmed: 10827969
Nature. 2017 Feb 23;542(7642):433-438
pubmed: 28135719
FASEB J. 2019 Apr;33(4):5287-5299
pubmed: 30698461
Cell Rep. 2021 Aug 3;36(5):109495
pubmed: 34348148
Nat Neurosci. 2018 Jul;21(7):996-1003
pubmed: 29867081
Genet Med. 2019 Sep;21(9):2043-2058
pubmed: 30842647
Stem Cell Reports. 2018 Nov 13;11(5):1211-1225
pubmed: 30392976
Mol Genet Metab. 2016 Jan;117(1):42-8
pubmed: 26647175
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Cell Rep. 2021 Aug 3;36(5):109483
pubmed: 34348157
Am J Hum Genet. 2019 Apr 4;104(4):758-766
pubmed: 30929739
Gene. 2001 Feb 7;264(1):113-22
pubmed: 11245985
Lancet. 2012 Nov 10;380(9854):1674-82
pubmed: 23020937
Hum Mol Genet. 2015 Mar 1;24(5):1457-68
pubmed: 25378553
Nat Neurosci. 2012 Jun 03;15(7):1007-14
pubmed: 22660478
Neuron. 2019 Aug 21;103(4):673-685.e5
pubmed: 31230762
Nat Rev Neurosci. 2019 Jan;20(1):34-48
pubmed: 30464208
Biol Psychiatry. 2017 Aug 1;82(3):224-232
pubmed: 28256214

Auteurs

R Asadollahi (R)

Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
Faculty of Engineering and Science, University of Greenwich London, Medway Campus, Chatham Maritime ME4 4TB, UK.

I Delvendahl (I)

Department of Molecular Life Sciences, University of Zurich, Zurich 8057, Switzerland.
Neuroscience Center Zurich, University of Zurich, Zurich 8057, Switzerland.

R Muff (R)

Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.

G Tan (G)

Functional Genomics Center Zurich, ETH Zurich and University of Zurich, Zurich 8057, Switzerland.

D G Rodríguez (DG)

Functional Genomics Center Zurich, ETH Zurich and University of Zurich, Zurich 8057, Switzerland.

S Turan (S)

Department of Stem Cell Biology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen 91054, Germany.

M Russo (M)

Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.

B Oneda (B)

Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.

P Joset (P)

Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.

P Boonsawat (P)

Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.

R Masood (R)

Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.

M Mocera (M)

Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.

I Ivanovski (I)

Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.

A Baumer (A)

Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.

R Bachmann-Gagescu (R)

Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.

R Schlapbach (R)

Functional Genomics Center Zurich, ETH Zurich and University of Zurich, Zurich 8057, Switzerland.

H Rehrauer (H)

Functional Genomics Center Zurich, ETH Zurich and University of Zurich, Zurich 8057, Switzerland.

K Steindl (K)

Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.

A Begemann (A)

Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.

A Reis (A)

Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen 91054, Germany.

J Winkler (J)

Department of Molecular Neurology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen 91054, Germany.
Center for Rare Diseases Erlangen, University Hospital Erlangen, Erlangen 91054, Germany.

B Winner (B)

Department of Stem Cell Biology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen 91054, Germany.
Center for Rare Diseases Erlangen, University Hospital Erlangen, Erlangen 91054, Germany.

M Müller (M)

Department of Molecular Life Sciences, University of Zurich, Zurich 8057, Switzerland.
Neuroscience Center Zurich, University of Zurich, Zurich 8057, Switzerland.
University of Zurich Clinical Research Priority Program (CRPP) Praeclare - Personalized prenatal and reproductive medicine, Zurich 8006, Switzerland.
University of Zurich Research Priority Program (URPP) AdaBD: Adaptive Brain Circuits in Development and Learning, Zurich 8006, Switzerland.

A Rauch (A)

Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
Neuroscience Center Zurich, University of Zurich, Zurich 8057, Switzerland.
University of Zurich Clinical Research Priority Program (CRPP) Praeclare - Personalized prenatal and reproductive medicine, Zurich 8006, Switzerland.
University of Zurich Research Priority Program (URPP) AdaBD: Adaptive Brain Circuits in Development and Learning, Zurich 8006, Switzerland.
University of Zurich Research Priority Program (URPP) ITINERARE: Innovative Therapies in Rare Diseases, Zurich 8006, Switzerland.
Zurich Center for Integrative Human Physiology, University of Zurich, Zurich 8057, Switzerland.
University Children's Hospital Zurich, University of Zurich, Zurich 8032, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH